ArticleNeurology and therapy2019

Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study).

Annette F Okai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.